Nobel Prize winner died of pancreatic cancer

Share This Post

Dr. Thomas A. Steitz died on October 9, 2018 at the age of 78, and died of pancreatic cancer. Steitz is the co-winner of the 2009 Nobel Prize in Chemistry.

Steitz’s research on the ribosome has had a profound impact, making the atomic structure of the ribosome more clear. The ribosome is the main force that leads the genes encoded into DNA to be “translated” into proteins. Steitz’s work is directly related to the biological mechanism that causes pancreatic cancer. As we all know, pancreatic cancer and other cancer types are caused by genetic changes. When errors or mutations occur in the genetic code, these errors can pass through the ribosome and cause the production of abnormal proteins. The activity of these abnormal proteins causes healthy cells to become cancer cells and spread in the body. Researchers are doing further research to design new targeted therapies to directly block the activity of abnormal proteins in pancreatic cancer cells.

The Pancreatic Cancer Action Network (PanCAN) is deeply grateful to Steitz for his contributions to understanding cell and molecular biology, and expresses his condolences to his family, friends and colleagues.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy